Combination Therapy with Stem Cell-Derived Immune Cells Boost Anti-Cancer Response

Invariant natural killer T (iNKT) cells are promising for cancer immunotherapy because they can coordinate broader immune responses, but sourcing enough functional cells is challenging. In a recent study, researchers from Japan showed that combining stem cell-derived iNKT cells with an immune-activating lipid compound can strongly suppress tumors in mice by training the body’s own T cells to recognize and remember cancer. These findings point to a more effective and scalable form of immunotherapy.